Senior Analyst, Biopharmaceuticals
Telephone: (212) 705-0407
Serge Belanger joined Needham & Company in 2009. Prior to Needham, Serge worked as a research associate at Fulcrum Global Partners and Susquehanna International Group covering the biotech and specialty pharma healthcare sectors. Previously, Serge joined Adolor Corporation, a biopharmaceutical company, as a senior research scientist, where he was involved with the discovery and development of novel opioid receptor targeted molecules and non-opioid pain therapeutics. Serge graduated from McGill University with a BSc, Biochemistry/Pharmacology, and an MSc, Pharmacology and Therapeutics. He obtained his MBA in Finance from the Stern School of Business at New York University.
Alan Carr, Ph.D.
Senior Analyst, CNS/Metabolic Disorders, Inflammatory & Infectious Disease
Telephone: (212) 705-0435
Alan Carr joined Needham & Company in 2006. From 2001 to 2006 Alan worked in Yale’s technology transfer group, the Office of Cooperative Research, where he out-licensed a number of technologies and therapeutic product candidates developed in Yale labs and helped establish start-up companies in the New Haven area. Prior to that he was at J. Bush & Co., a New Haven investment firm, where he covered companies in the research tool and healthcare space. His post-doctoral work was centered on the regulation of neuronal development during embryogenesis. He earned his undergraduate degree at Albion College and earned his Ph.D. in Molecular Biophysics and Biochemistry from Yale University.
Mike Matson, CFA
Senior Analyst, Medical Technologies & Diagnostics
Telephone: (212) 705-0346
Mike Matson joined Needham & Company in 2013 covering Medical Technologies & Diagnostics. Prior to joining Needham, Mike spent nine years covering the medical supplies and devices industry for Mizuho Securities and Wells Fargo Securities. He previously worked in the medical device industry for Stryker's Orthopaedics and Endoscopy divisions in marketing and product development. Mike was ranked first for earnings estimating in the medical device industry in the 2013 FT/StarMine World's Top Analysts survey, ninth in the orthopedic subsector in the 2010 Greenwich Associates survey, second for stock picking in the medical device industry in the 2008 FT/StarMine World's Top Analysts survey, and fourth in the medical device industry for stock picking in the 2007 Wall Street Journal Best on the Street. Mike has a BS in Mechanical Engineering from North Carolina State University with a minor in Economics and a MBA from Duke University's Fuqua School of Business with a concentration in Health Sector Management. Mike holds a medical device patent (U.S. patent 6,919,914).
Chad Messer, Ph.D.
Senior Analyst, Biotechnology
Telephone: (212) 705-0317
Chad Messer joined Needham & Company in 2012. Prior to Needham, he was a research analyst at Piper Jaffray and Paramount Biocapital covering the biotechnology industry. In addition, Chad worked at Genaissance Pharmaceuticals, a New Haven, CT biotechnology company, where he held a number of positions, including manager of corporate development. He has over a dozen years of corporate and Wall Street experience with the biotech industry. Chad holds a Ph.D. in Pharmacology from Yale, received a MBA from NYU Masters of Business degree in Finance and a Bachelor’s degree in Biology from Yale.
Elliot Wilbur, CFA
Senior Analyst, Specialty Pharmaceuticals
Telephone: (212) 705-0333
Elliot Wilbur joined Needham & Company in 2008. Elliot covers the drug delivery, specialty, and generic pharmaceutical sectors for Needham & Company focusing on small-to-mid-size emerging pharmaceutical franchises. Prior to joining Needham, Elliot was a senior equity research analyst covering the specialty pharmaceutical sector for CIBC World Markets, a position held since 2001. Before joining CIBC’s healthcare research team, he spent three years working for the firm's equity portfolio strategy group designing proprietary multi-factor stock selection models for use in sector and industry weighting determinations. Before joining CIBC World Markets, he was a research associate with William O'Neil & Co. focusing on fundamental and technical analysis of U.S. equities. Elliot has been recognized for his stock selection skill in The Wall Street Journal’s All-Star Analyst survey for the past three years. He was also ranked among the top five in his sector in The Financial Times and Starmine’s “Starmine Awards” 2010 analyst survey. He has consistently maintained one of the broadest universes among specialty pharmaceutical analysts on Wall Street. He is a summa cum laude graduate of Robert Morris College, where he received a BS in Finance and a minor in Quantitative Analysis and earned an MBA in Finance from the Anderson School of Business at UCLA.